These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 3609475

  • 1. Thrombogenicity of factor IX complex: in vivo investigation.
    Aronson DL, Menache D.
    Dev Biol Stand; 1987; 67():149-55. PubMed ID: 3609475
    [Abstract] [Full Text] [Related]

  • 2. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM.
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [Abstract] [Full Text] [Related]

  • 3. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV.
    Thromb Haemost; 1991 Nov 01; 66(5):609-13. PubMed ID: 1803625
    [Abstract] [Full Text] [Related]

  • 4. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, Barrowcliffe TW.
    Thromb Haemost; 1995 Apr 01; 73(4):675-9. PubMed ID: 7495077
    [Abstract] [Full Text] [Related]

  • 5. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF, Drummond O, MacGregor IR.
    Thromb Haemost; 1992 Nov 10; 68(5):511-5. PubMed ID: 1455396
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
    Kim HC, Matts L, Eisele J, Czachur M, Saidi P.
    Semin Hematol; 1991 Jul 10; 28(3 Suppl 6):15-9. PubMed ID: 1780766
    [No Abstract] [Full Text] [Related]

  • 7. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion.
    Aronson DL, Thomas DP.
    Thromb Haemost; 1985 Dec 17; 54(4):866-70. PubMed ID: 3879019
    [Abstract] [Full Text] [Related]

  • 8. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.
    Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG.
    Blood; 1982 Feb 17; 59(2):401-7. PubMed ID: 7034817
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo.
    Hedner U, Nilsson IM, Bergentz SE.
    Thromb Haemost; 1976 Apr 30; 35(2):386-95. PubMed ID: 989639
    [Abstract] [Full Text] [Related]

  • 11. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M, Golino P, Cirillo P, Pascucci I, Scognamiglio A, Ravera A, Esposito N, Battaglia C, Guarino A, Chiariello M.
    Cardiologia; 1996 Jan 30; 41(1):51-8. PubMed ID: 8697470
    [Abstract] [Full Text] [Related]

  • 12. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP, Klessen C, Jablonowski C, Meerbach W, Dornheim G.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984 Jan 30; 111(5):645-61. PubMed ID: 6083940
    [Abstract] [Full Text] [Related]

  • 13. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM.
    Thromb Haemost; 1993 Nov 15; 70(5):768-73. PubMed ID: 8128433
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I.
    Thromb Haemost; 2007 Oct 15; 98(4):790-7. PubMed ID: 17938803
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model.
    McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM.
    Clin Lab Sci; 2007 Oct 15; 20(2):99-105. PubMed ID: 17557708
    [Abstract] [Full Text] [Related]

  • 16. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J.
    Haematologica; 2000 Oct 15; 85(10 Suppl):15-20. PubMed ID: 11187863
    [Abstract] [Full Text] [Related]

  • 17. Assembly of the intrinsic factor X activating complex--interactions between factor IXa, factor VIIIa and phospholipid.
    van Dieijen G, van Rijn JL, Govers-Riemslag JW, Hemker HC, Rosing J.
    Thromb Haemost; 1985 Jun 24; 53(3):396-400. PubMed ID: 3931288
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV, Williams AE.
    Thromb Haemost; 1980 Oct 31; 44(2):81-6. PubMed ID: 6779401
    [Abstract] [Full Text] [Related]

  • 19. A human antibody that binds to the gamma-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo.
    Refino CJ, Himber J, Burcklen L, Moran P, Peek M, Suggett S, Devaux B, Kirchhofer D.
    Thromb Haemost; 1999 Sep 31; 82(3):1188-95. PubMed ID: 10494786
    [Abstract] [Full Text] [Related]

  • 20. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T, Read MS, Bellinger DA, Brinkhous KM, Kay MA.
    Nat Med; 1999 Jan 31; 5(1):64-70. PubMed ID: 9883841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.